Welcome to our dedicated page for Taro Pharmaceutical Industries Ltd. news (Ticker: TARO), a resource for investors and traders seeking the latest updates and insights on Taro Pharmaceutical Industries Ltd. stock.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) is a global, research-based pharmaceutical company founded in 1950. Specializing in the development, manufacturing, and marketing of prescription and over-the-counter pharmaceutical products, Taro operates across key therapeutic categories including dermatological, cardiovascular, neuropsychiatric, and anti-inflammatory treatments. The company’s product portfolio features semi-solid formulations like creams and ointments, as well as liquids, capsules, and tablets.
Taro’s innovative research initiatives and niche market strategies have positioned the company as a leader in the specialty pharmaceutical sector, achieving some of the highest gross margins in the industry. The bulk of Taro's revenue is derived from the United States, with a significant presence in Canada, Israel, and other international markets.
Recently, Taro has entered into a definitive merger agreement with Sun Pharmaceutical Industries Ltd., its controlling shareholder. Sun Pharma has agreed to acquire all outstanding ordinary shares of Taro at US$43.00 per share, a 48% premium over the closing price on May 25, 2023. This merger is anticipated to be completed in the first half of 2024, pending various closing conditions, including shareholder approvals.
The merger aims to leverage Sun Pharma’s extensive global capabilities, enhancing Taro’s ability to serve patients and healthcare professionals worldwide. Post-merger, Taro will become a privately-held company, delisting from the NYSE.
For more comprehensive details about the company's operations, financials, and the ongoing merger, visit Taro's official website or the SEC’s online resources.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported its financial results for the quarter and nine months ended December 31, 2021. Net sales decreased to $139.0 million, while gross profit rose to $76.0 million, representing a margin of 54.7%. The company faced a net income drop to $26.3 million from $32.9 million. For the nine months, net sales increased to $418.1 million, but gross profit fell to $215.8 million. Legal settlements related to antitrust issues significantly impacted finances. Cash and equivalents fell to $1.3 billion due to DOJ payments and share repurchases. FDA approvals for new drug applications were also noted.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced it will release financial results for the quarter and nine months ended December 31, 2021, after market close on January 27, 2022. The financial report will be available on Taro’s official website. Taro is committed to delivering high-quality healthcare products through its extensive research and development efforts.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has appointed William J. Coote as Vice President, Chief Financial Officer, and Chief Accounting Officer, effective immediately. Mr. Coote brings over 25 years of financial executive experience, having served as Taro's AVP, Treasurer, and Business Finance since 2008. His previous roles include positions at Bowne & Co., Prudential Realty, Merrill Lynch, and Ernst & Young.
CEO Uday Baldota expressed confidence in Coote's leadership, highlighting his track record and experience as vital for executing the company's strategy.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for the quarter and six months ended September 30, 2021. For the quarter, net sales were $132.0 million, down $10.9 million from the previous year, with gross profit of $62.0 million (47% of net sales) decreasing significantly. Operating income fell to $24.4 million from $40.9 million, reflecting increased tax expenses and settlements related to DOJ investigations. For the first half, net sales increased to $279.1 million, but gross profit decreased. The company continues to focus on strategic opportunities and recently received FDA approval for a new product.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will release its financial results for the quarter and six months ended September 30, 2021, after the market closes on Thursday, October 28, 2021. The results will be accessible on Taro's official website. Taro is a multinational pharmaceutical company focused on the discovery, development, manufacturing, and marketing of high-quality healthcare products.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for the quarter ended June 30, 2021, showing net sales of $147.1 million, a 25.1% increase from the previous year. Gross profit was $77.7 million, but the gross margin decreased to 52.8%. Operating loss narrowed to $(19.2) million, while net loss improved to $(18.8) million. Diluted earnings per share, excluding settlements, rose to $1.09. Cash flow from operations totaled $44.0 million. The company repurchased 254,717 shares during the quarter as part of its $300 million repurchase program.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) will announce its financial results for the quarter ending June 30, 2021, on July 27, 2021, after market close. Investors can access the financial results on Taro's official website.
The company focuses on developing and marketing high-quality healthcare products to meet customer needs.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has announced the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving to explore other opportunities. The CEO, Uday Baldota, expressed gratitude for her contributions, particularly during the COVID-19 pandemic. The company is now in the process of searching for her successor.
Taro remains committed to its mission of developing high-quality healthcare products.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has made its Annual Report on Form 20-F for the fiscal year ending March 31, 2021, available. This report can be accessed in the Investor Relations section of Taro's website or through the SEC’s website. Hard copies can be requested free of charge. Taro continues to focus on meeting customer needs through the development and marketing of high-quality healthcare products.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) reported unaudited financial results for the quarter and year ended March 31, 2021. Net sales decreased to $148.3 million for the quarter and $549.0 million for the year, down by $26.6 million and $95.8 million, respectively. Gross profit for the quarter was $76.9 million (51.9% of net sales) compared to 58.5% the previous year. The company faced substantial settlements and loss contingencies totaling $558.9 million. Taro recorded a net loss of $(386.7) million for the year, leading to a diluted loss per share of $(10.12). Despite challenges, Taro announced new FDA approvals and launched a skincare brand, Bee Rx™.
FAQ
What is the current stock price of Taro Pharmaceutical Industries Ltd. (TARO)?
What is the market cap of Taro Pharmaceutical Industries Ltd. (TARO)?
What does Taro Pharmaceutical Industries Ltd. specialize in?
What are the primary products Taro offers?
Where does Taro generate most of its revenue?
Who is Taro merging with?
What is the value of the merger deal with Sun Pharma?
When is the merger with Sun Pharma expected to be completed?
What will happen to Taro's shares after the merger?
How can I get more details about the merger?
Why is Taro merging with Sun Pharma?
What are the benefits of Taro’s niche market strategy?
